Analyses of mRNA expression databases of AML patients receiving curative treatments with ara-C and idarubicin60 revealed that both low- and high-PARP1-expressing subgroups with FLT3 wild-type M4/M5 AML had inferior survival as compared with the median-expressing group (Figure 5C). This evidence concerns the gene PARP1 and acute myeloid leukemia.